

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-17. (cancelled)

18. (New) A peptide consisting of a GLP-1 peptide and Waa-(Xaa)_n-Yaa (in which Waa is Arg or Lys, Xaa is Lys, n is an integer of 1 to 9, and Yaa is Arg or Arg-NH₂) added to the C-terminus of the GLP-1 peptide, wherein the GLP-1 peptide is selected from the group consisting of GLP-1(7-35), [Ser⁸]-GLP-1(7-35), [Gln²⁶, Asn³⁴]-GLP-1(7-35), and [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35).

19. (New) The peptide according to claim 18, wherein the GLP-1 peptide is [Ser⁸]-GLP-1(7-35).

20. (New) The peptide according to claim 18, wherein the GLP-1 peptide is [Gln²⁶, Asn³⁴]-GLP-1(7-35).

21. (New) The peptide according to claim 18, wherein the GLP-1 peptide is [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35).

22. (New) The peptide according to claim 18, wherein n is an integer of 3 to 5.

23. (New) The peptide according to claim 18, which has a higher efficiency of transmucosal absorption than that of naturally occurring GLP-1.

24. (New) A pharmaceutical composition for transmucosal administration containing as an active ingredient a peptide consisting of a GLP-1 peptide and Waa-(Xaa)_n-Yaa (in which Waa is Arg or Lys, Xaa is Lys, n is an integer of 1 to 9, and Yaa is Arg or Arg-NH₂) added to the C-terminus of the GLP-1 peptide, wherein the GLP-1 peptide is selected from the group consisting of GLP-1(7-35), [Ser⁸]-GLP-1(7-35), [Gln²⁶, Asn³⁴]-GLP-1(7-35), and [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35).

25. (New) The pharmaceutical composition according to claim 24, which is used for nasal administration.

26. (New) The pharmaceutical composition according to claim 24, which is used in treatment of non-insulin dependent chronic diabetes mellitus, treatment of insulin dependent chronic diabetes mellitus, treatment of obesity and/or suppression of appetite.

27. (New) The pharmaceutical composition according to claim 24, wherein the GLP-1 peptide is [Ser⁸]-GLP-1(7-35).

28. (New) The pharmaceutical composition according to claim 24, wherein the GLP-1 peptide is [Gln²⁶, Asn³⁴]-GLP-1(7-35).

29. (New) The pharmaceutical composition according to claim 24, wherein the GLP-1 peptide is [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35).

30. (New) A method for treating non-insulin dependent diabetes mellitus, insulin dependent diabetes mellitus and/or obesity which comprises transmucosally administering to the patient a pharmaceutical composition containing as an active ingredient a peptide consisting of a GLP-1 peptide and Waa-(Xaa)_n-Yaa (in which Waa is Arg or Lys, Xaa is Lys, n is an integer of 1 to 9, and Yaa is Arg or Arg-NH₂) added to the C-terminus of the GLP-1 peptide, wherein the GLP-1 peptide is selected from the group consisting of GLP-1(7-35), [Ser⁸]-GLP-1(7-35), [Gln²⁶, Asn³⁴]-GLP-1(7-35), and [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35).

31. (New) The method according to claim 30, wherein the GLP-1 peptide constituting the active ingredient of the pharmaceutical composition is [Ser⁸]-GLP-1(7-35).

32. (New) The method according to claim 30, wherein the GLP-1 peptide constituting the active ingredient of the pharmaceutical composition is [Gln²⁶, Asn³⁴]-GLP-1(7-35).

33. (New) The method according to claim 30, wherein the GLP-1 peptide constituting the active ingredient of the pharmaceutical composition is [Ser⁸, Gln²⁶, Asn³⁴]-GLP-1(7-35).